Publications and Presentations

Publications

A Second Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial of Cytisinicline in Adult Smokers (ORCA-3)
JAMA Internal Medicine, April 2025

A Randomized Placebo-Controlled Clinical Trial of Cytisinicline for Nicotine E-Cigarette Cessation (ORCA-V1)
JAMA Internal Medicine, May 2024

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial of Cytisinicline in Adult Smokers (ORCA-2)
JAMA, July 2023

Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials
Thorax, September 2025

Comparative Effectiveness of Cytisinicline and Varenicline for Smoking Cessation: A Matching-Adjusted Indirect Comparison (MAIC)
Journal of Health Economics and Outcomes Research, May 2026

Receptor selectivity of cytisinicline: minimal 5-HT3 binding may explain lower incidence of nausea in smoking cessation therapy
Nicotine & Tobacco Research, September 2026

ORCA-1: A multicenter, double-blind, randomized, placebo-controlled Phase 2b trial of cytisinicline in adult smokers
Nicotine & Tobacco Research, October 2021

Presentations

ATS 2026 Annual Meeting

Comparative effectiveness of cytisinicline and varenicline for smoking cessation: A matching-adjusted indirect comparison (MAIC)

Cytisinicline for cigarette smoking and e-cigarette vaping cessation: Long-term safety data from the ORCA-OL clinical trial

SRNT 2026

Efficacy of Cytisinicline for Smoking Cessation in Adults with and without Multiple Prior Quit Attempts or Prior Pharmacotherapy Use: Pooled Analysis of Two Phase 3 Trials

Cytisinicline in Adult Smokers: Post-Trial Survey From ORCA-OL

ASCO 2026

Cytisinicline for smoking cessation among patients with a history of cancer: A post-hoc analysis from two phase 3 clinical trials.